Michel Vounatsos, Biogen CEO (Biogen via YouTube)

April 22, 2021 09:29 AM EDTUpdated April 23, 04:55 AM

Damn the critics, Biogen CEO Vounatsos orders full speed ahead on prepping a controversial aducanumab launch as FDA decision looms

Right now one of the most interesting parlor games on Wall Street is offering odds on Biogen’s chances of getting an FDA OK on their …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

FDA chief to senators: 3,000+ staff departures won't delay user fee targets

House passes Trump tax bill with PBM and orphan drug reforms included

Post-Hoc: AI bio needs to heed the overhyped history of CRISPR

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?